0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1963 Views 
0 Saved
0 Vote 1 Contributor1963 Views 0 SavedYou might also be interested in
No, not every cancer patient needs chemotherapy. Treatment depends on the type and stage of cancer. Some may need surgery, radiation, or newer therapies like immunotherapy. Your doctor will recommend the best plan for your condition. I’m scared chemotherapy will make me lose my hair. Is there any....
A number of masses can be found within the female breast but not all of them are cancerous. So, don’t panic if you find a mass. Among the benign masses, most are only an inconvenience and have no threat, but some may be associated with increased long-term risk of breast cancer. A fibroadenoma is a ....
Charges of biopsy
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.